3 Catalysts That Could Send Teva Stock to $40 and Beyond

By Keith Speights – Apr 18, 2026 at 4:44AM ESTKey PointsFDA approval of long-acting schizophrenia drug olanzapine could be Teva's biggest near-term catalyst.Teva's specialty drugs continue to gain momentum.The drugmaker should also experience a biosimilar boom over the next couple of years.After a multi-year slump, Teva Pharmaceutical Industries Limited (TEVA +3.65%) is on a roll. Shares of the Israel-based drugmaker have soared more than 130% over the last 12 months. Could Teva's momentum continue? Wall Street thinks so. Twelve of the 15 analysts surveyed by S&P Global (SPGI +1.32%) in April rated the pharmaceutical stock as a "buy" or "strong buy." There are three specific catalysts that could send Teva stock to $40 -- and perhaps beyond. Image source: Getty Images. 1. Olanzapine approval Roughly three months ago, the U.S. Food and Drug Administration (FDA) accepted Teva's New Drug Application (NDA) for olanzapine extended-release injectable suspension (TEV-'749) for the treatment of schizophrenia in adults. An approval decision is expected later this year. Evercore ISI (NYSE: EVR) analyst Umer Raffat views the potential approval of olanzapine as Teva's "most meaningful catalyst." I think that Raffat is right. Although olanzapine is already one of the most commonly prescribed antipsychotics for treating schizophrenia, there are no long-acting formulations of the drug for which the FDA doesn't require a Risk Evaluation and Mitigation Strategy (REMS). Under a REMS, the drug must be administered in a certified facility. Patients must also be monitored for three hours after the injection. Teva's long-acting olanzapine formulation, which the company doesn't expect to require a REMS, should significantly increase treatment adherence. Olanzapine and Uzedy, another long-acting drug marketed by Teva for treating schizophrenia and bipolar disorder, could together achieve peak annual sales of more than $2 billion. 2. Specialty drug momentum Another potential catalyst for Teva is the acceleration of commercial momentum for its specialty drugs. Austedo ranks as the most important member of this group. The drug is approved as a treatment for tardive dyskinesia (TD) and Huntington's disease chorea (involuntary, jerky muscle movements). Austedo generated sales of $2.26 billion in 2025, a 34% year-over-year increase from 2024. Teva expects the drug to rake in between $2.4 billion and $2.55 billion this year. Migraine therapy Ajovy and Uzedy are also key parts of Teva's specialty drug success. Ajovy's sales jumped 30% year over year in 2025 to $673 million. Uzedy's sales soared 63% to $191 million. ExpandNYSE: TEVATeva Pharmaceutical IndustriesToday's Change(3.65%) $1.14Current Price$32.40Key Data PointsMarket Cap$38BDay's Range$31.27 - $32.8152wk Range$13.04 - $37.34Volume4.5MAvg Vol7.8MGross Margin51.82% 3. Biosimilar boom We can't overlook Teva's biosimilar boom. The company expects to launch six new biosimilars in 2026 and 2027. Teva could soon battle Amgen (AMGN +1.69%) with new biosimilars to bone disease drugs Prolia and Xgeva. It could threaten Johnson & Johnson (JNJ 0.11%) in the autoimmune disease market with Simponi and Simponi Aria biosimilars. Teva could also soon secure approval for a biosimilar to Regeneron's (REGN +0.61%) eye disease drug Eylea. Jefferies (JEF +3.37%) thinks 2026 will be a pivotal year for Teva to convince investors that its research and development pipeline can deliver. However, Teva has more biosimilars on the way in 2028 and later. The company now boasts the biopharmaceutical industry's second-largest biosimilar portfolio. What could derail Teva's rise? These three catalysts might just propel Teva to $40 or higher in the near future. But what could detail the stock's rise? A stock market crash would likely drag Tesla down in its wake. Major pipeline or regulatory setbacks could bring the stock's momentum to a screeching halt. Slowing Austedo sales would probably do the trick as well. The good news is that Teva's pipeline is de-risked to some extent, with several late-stage programs. And thanks to a forward earnings multiple of only 11.7, Teva is practically a value stock. I wouldn't bet the farm on Teva's share price reaching $40 within the next 12 months. However, I wouldn't bet against it happening, either.Read NextApr 17, 2026 •By David Jagielski, CPABetter Long-Term Buy: Eli Lilly or Viking Therapeutics?Apr 17, 2026 •By Selena MaranjianThe Healthcare Stock Built for Investors Who Prioritize Capital PreservationApr 17, 2026 •By Motley Fool StaffThe Psychedelic Revolution in Mental HealthcareApr 17, 2026 •By Prosper Junior BakinyIs This the Biggest Game-Changer in Lilly's 150-Year History?Apr 17, 2026 •By Prosper Junior BakinyBetter Pharma Dividend Stock: Novartis vs. MerckApr 17, 2026 •By Prosper Junior BakinyWhere Will Green Thumb Industries Stock Be in 5 Years?About the AuthorKeith Speights is a contributing Motley Fool healthcare analyst covering publicly traded companies across pharmaceuticals, biotechnology, medical devices, technology, and marijuana. Prior to The Motley Fool, Keith was CEO of Constant Care Technology, a healthcare technology company; vice president of American HealthTech, a healthcare software company; and a director of operations for Blue Cross Blue Shield of Mississippi, a health insurer. He holds a B.S. in Industrial Engineering from Mississippi State University.TMFFishBizStocks MentionedTeva Pharmaceutical IndustriesNYSE: TEVA$32.45(+3.81%)+$1.19Johnson & JohnsonNYSE: JNJ$234.18(-0.15%)-$0.36S&P GlobalNYSE: SPGI$442.57(+1.32%)+$5.78Regeneron PharmaceuticalsNASDAQ: REGN$750.57(+0.61%)+$4.57AmgenNASDAQ: AMGN$355.15(+1.65%)+$5.76Jefferies Financial GroupNYSE: JEF$48.13(+3.37%)+$1.57EvercoreNYSE: EVR$363.64(+1.71%)+$6.12*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.